ES2101449T3 - Inhibicion de la seborrea y el acne. - Google Patents

Inhibicion de la seborrea y el acne.

Info

Publication number
ES2101449T3
ES2101449T3 ES94309474T ES94309474T ES2101449T3 ES 2101449 T3 ES2101449 T3 ES 2101449T3 ES 94309474 T ES94309474 T ES 94309474T ES 94309474 T ES94309474 T ES 94309474T ES 2101449 T3 ES2101449 T3 ES 2101449T3
Authority
ES
Spain
Prior art keywords
seborrhea
acne
inhibition
pirrolidine
hexamethyleneimine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94309474T
Other languages
English (en)
Inventor
George Joseph Cullinan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2101449T3 publication Critical patent/ES2101449T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

UN METODO PARA INHIBIR EL ACNE Y LA SEBORREA COMPRENDIENDO ADMINISTRAR A UNA MUJER EN LA NECESIDAD DE TRATAMIENTO UNA CANTIDAD EFECTIVA DE UN COMPONENTE QUE TIENE LA FORMULA (I) EN DONDE EN DONDE R1 Y R3 SON INDEPENDIENTEMENTE HIDROGENO, -CH3, (ALQUILO C1-C6)-CO O CO-AR, EN DONDE AR ES FENILO OPCIONALMENTE SUSTITUIDO; R2 ES SELECCIONADO DEL GRUPO QUE CONSTA DE PIRROLIDINA, HEXAMETILENEIMINO, Y PIPERIDINO; O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE SU SOLVENTE.
ES94309474T 1993-12-21 1994-12-19 Inhibicion de la seborrea y el acne. Expired - Lifetime ES2101449T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,970 US5439923A (en) 1993-12-21 1993-12-21 Method of inhibiting seborrhea and acne

Publications (1)

Publication Number Publication Date
ES2101449T3 true ES2101449T3 (es) 1997-07-01

Family

ID=22622023

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94309474T Expired - Lifetime ES2101449T3 (es) 1993-12-21 1994-12-19 Inhibicion de la seborrea y el acne.

Country Status (18)

Country Link
US (2) US5439923A (es)
EP (1) EP0659416B1 (es)
JP (1) JPH07196497A (es)
KR (1) KR950016731A (es)
CN (1) CN1107706A (es)
AT (1) ATE150307T1 (es)
AU (1) AU8154794A (es)
CA (1) CA2138491A1 (es)
CZ (1) CZ321494A3 (es)
DE (1) DE69402165T2 (es)
DK (1) DK0659416T3 (es)
ES (1) ES2101449T3 (es)
GR (1) GR3023378T3 (es)
HU (1) HUT71481A (es)
IL (1) IL112042A0 (es)
NO (1) NO311243B1 (es)
RU (1) RU94044453A (es)
ZA (1) ZA9410086B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GR1002807B (el) * 1996-06-20 1997-11-13 Lavipharm A.E. Συστημα για την τοπικη θεραπεια της ακμης και μεθοδος παραγωγης του
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1085913A1 (en) * 1998-06-08 2001-03-28 Ferris Corporation Analgesic and antinociceptive methods
CZ20013912A3 (cs) 1999-05-04 2002-05-15 Strakan Limited Androgen glykosid, sloučenina, testosteron-ß-D-glukosid, 5 alfa-Dihydrotestosteron- 17ß-D-glukosid, farmaceutický prostředek a pouľití sloučeniny
FR2804865B1 (fr) * 2000-02-15 2003-11-28 Oreal Utilisation des corps gras particuliers permettant de modifier les proprietes physio-chimiques de la peau et/ou des muqueuses en tant qu'agents empechant ou diminuant l'adhesion des micro-organismes sur ces dernieres
US6495158B1 (en) 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US8048919B2 (en) * 2004-06-28 2011-11-01 Archer Daniels Midland Company Use of ethyl lactate as an excipient for pharmaceutical compositions
WO2006060475A1 (en) * 2004-12-03 2006-06-08 Nu-Tein Co., Inc. Method for treating skin disorders with xanthophylls
FR2953833B1 (fr) 2009-12-10 2012-01-13 Galderma Res & Dev Derives de nouveaux peroxydes, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique pour le traitement ou la prevention de l'acne
FR2953832B1 (fr) 2009-12-10 2012-01-13 Galderma Res & Dev Derives de nouveaux peroxydes, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique pour le traitement ou la prevention de l'acne

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
IL95584A (en) * 1989-09-07 1995-03-15 Abbott Lab Indole-, benzoporene- and benzothiophene compounds including lipoxygenase-inhibiting compounds and pharmaceutical compounds containing them
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
US5688812A (en) 1997-11-18
NO944918L (no) 1995-06-22
NO311243B1 (no) 2001-11-05
EP0659416B1 (en) 1997-03-19
CA2138491A1 (en) 1995-06-22
US5439923A (en) 1995-08-08
ATE150307T1 (de) 1997-04-15
RU94044453A (ru) 1996-10-10
CN1107706A (zh) 1995-09-06
EP0659416A2 (en) 1995-06-28
HU9403667D0 (en) 1995-02-28
DK0659416T3 (da) 1997-08-18
HUT71481A (en) 1995-11-28
ZA9410086B (en) 1996-06-19
NO944918D0 (no) 1994-12-19
CZ321494A3 (en) 1995-09-13
GR3023378T3 (en) 1997-08-29
KR950016731A (ko) 1995-07-20
IL112042A0 (en) 1995-03-15
EP0659416A3 (en) 1995-09-06
AU8154794A (en) 1995-06-29
JPH07196497A (ja) 1995-08-01
DE69402165T2 (de) 1997-07-17
DE69402165D1 (de) 1997-04-24

Similar Documents

Publication Publication Date Title
ES2102154T3 (es) Inhibicion de trombina.
ES2119094T3 (es) Inhibicion de la hemorragia uterina disfuncional.
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
GEP19991706B (en) (54) Heteroarylpiperidines, Pyrrolidines and Piperazines and Their Use As Antipsychotics and Analgetics
IL111995A0 (en) Methods of treating menstrual symptoms and compositions therefor
DE69402165D1 (de) Hemmung von Seborrhoe und Akne
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
PT651999E (pt) Metodos de inibicao da fibrose uterina
ES2154669T3 (es) Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para la inhibicion de la degradacion del cartilago.
PT652004E (pt) Metodos para tratar neoplasmas resistentes
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법
ES2195313T3 (es) Derivados de imino-aza-antraciclinona para el tratamiento de la amiloidosis.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
ECSP961892A (es) Procedimientos para inhibir el inhibidor del activador del plasminogeno 1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 659416

Country of ref document: ES